IL–10 overexpression was found to be associated with worse 3-year OS in both solid tumors (OR = 3.38, 95% CI = 2.22 to 5.15, P < 0.0001) and hematological malignances (OR = 3.29, 95% CI = 2.28 to 4.74, P < 0.0001) (Fig 5). Here, IL10 is linked to hematologic disorder.